Previous 10 | Next 10 |
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today a...
Silence Therapeutics press release (NASDAQ:SLN): Q1 GAAP EPS of 8.6p. Revenue of £5.7M (+83.9% Y/Y). For further details see: Silence Therapeutics GAAP EPS of 8.6p, revenue of £5.7M
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today r...
Silence Therapeutics (NASDAQ:SLN) announced that it will receive a $2M cash payment from Hansoh Pharmaceutical post the achievement of an undisclosed preclinical milestone. Both the companies entered a collaboration in October 2021 to develop siRNAs leveraging Silence's proprietary ...
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it will receive a $2.0 million cash paymen...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today a...
– Results were simultaneously presented today in a late breaker at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22) in Washington, D.C. Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”...
– SLN360 reduced Lp(a) – a key genetic risk factor for heart disease - by up to 98% with reductions of up to 81% persisting at 150 days – Results were simultaneously published in The Journal of the American Medical Association (JAMA) Sile...
Silence Therapeutics plc (NASDAQ:SLN) will receive a $3M research milestone payment from Mallinckrodt (OTCPK:MNKKQ) as the companies announced filing of a clinical trial application (CTA) for SLN501 targeting complement-mediated diseases. In July 2019, Silence and Mallinckrodt began...
Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic aci...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...